ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ELDN Eledon Pharmaceuticals Inc

3.05
0.11 (3.74%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 144,931
Bid Price 2.70
Ask Price 14.00
News (4)
Day High 3.08

Low
1.07

52 Week Range

High
3.349

Day Low 2.935
Share Name Share Symbol Market Stock Type
Eledon Pharmaceuticals Inc ELDN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.11 3.74% 3.05 23:00:09
Open Price Low Price High Price Close Price Previous Close
2.94 2.935 3.08 3.03 2.94
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,301 144,931 US$ 3.01 US$ 436,464 - 1.07 - 3.349
Last Trade Type Quantity Price Currency
17:16:27 formt 162 US$ 3.05 USD

Eledon Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
73.08M 24.20M - 0 -40.33M -1.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eledon Pharmaceuticals News

Date Time Source News Article
6/14/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/14/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/14/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/14/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/06/202415:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
6/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
6/03/202415:01GlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial..
5/30/202415:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
5/24/202415:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of..
5/15/202406:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/13/202415:30Edgar (US Regulatory)Form 8-K - Current report
5/09/202406:30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ELDN Message Board. Create One! See More Posts on ELDN Message Board See More Message Board Posts

Historical ELDN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.793.202.712.89136,7900.269.32%
1 Month2.803.3492.302.90181,5780.258.93%
3 Months2.073.3491.522.40209,9240.9847.34%
6 Months1.433.3491.352.21135,7811.62113.29%
1 Year1.753.3491.071.91105,9981.3074.29%
3 Years8.808.851.073.0181,855-5.75-65.34%
5 Years15.8022.911.073.9978,625-12.75-80.70%

Eledon Pharmaceuticals Description

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Your Recent History

Delayed Upgrade Clock